FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Kinetics topics
Medical Device
Polypeptide
Nucleic Acid
Nucleic Acids
Specificity
Surfactant
Enhancement
Scattering
Electrolyte
Conductive Elements
Amplification
Red Blood Cell
Red Blood Cells
Antibodies
Luciferase

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Kinetics patents



      
           
This page is updated frequently with new Kinetics-related patent applications. Subscribe to the Kinetics RSS feed to automatically get the update: related Kinetics RSS feeds. RSS updates for this page: Kinetics RSS RSS


Date/App# patent app List of recent Kinetics-related patents
12/18/14
20140371436
 Novel polyene compound, method for preparing the same, and antifungal drug comprising novel polyene compound asactive ingredient patent thumbnailnew patent Novel polyene compound, method for preparing the same, and antifungal drug comprising novel polyene compound asactive ingredient
The present invention relates to a novel polyene compound similar to nystatin, a method for preparing the same, and an antifungal drug comprising the novel polyene compound as an active ingredient. Compared to nystatin comprising one sugar, nnp, which is the polyene compound similar to nystatin, displays 300 times higher solubility and ten times lower cytotoxicity while maintaining antifungal activity, and thus can be useful in developing a novel polyene antifungal agent having improved solubility and less toxicity in terms of pharmacokinetics..
12/18/14
20140371181
 Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens patent thumbnailnew patent Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
Prodrugs of c-17-heterocyclic-steroidal drugs providing improved oral bioavailability and phamacokinetics are described. The drugs are inhibitors of human cyp 17 enzyme, as well as potent antagonists of both wild type and mutant androgen receptors (ar), and are useful for the treatment of urogenital and/or androgen-related cancers, diseases and/or conditions, such as human prostate cancer, breast cancer, and prostate hyperplasia.
12/18/14
20140370108
 Pharmacokinetics of s-adenosylmethionine formulations patent thumbnailnew patent Pharmacokinetics of s-adenosylmethionine formulations
Compositions and methods to improve the pharmacokinetic profile of s-adenosylmethionine (same) are provided, as are methods of treating various disorders using same formulations with improved pharmacokinetic profiles. More specifically, the invention is directed to methods of treating a disease or disorder in a subject and/or improving the nutritional status of a subject by administering formulations exhibiting improved pharmacokinetic profiles of exogenous same.
12/18/14
20140370001
 Ige antibodies for the inhibition of tumor metastasis patent thumbnailnew patent Ige antibodies for the inhibition of tumor metastasis
The present invention provides novel ige antibodies useful for inhibiting or preventing metastatic cancer. Also provided are methods to inhibit tumor metastasis by modulating the activity of at least one non-tumor cell, treating a patient to inhibit or prevent tumor metastases of a primary solid tumor, treating metastatic carcinoma, reducing metastasis of carcinoma cells, and reducing the growth kinetics of a primary solid tumor or a metastasized cell or tumor..
12/11/14
20140365640
 Method, apparatus, and computer program product for performance analytics determining location based on real-time data for proximity and movement of objects patent thumbnailMethod, apparatus, and computer program product for performance analytics determining location based on real-time data for proximity and movement of objects
Systems, methods, apparatuses, and computer readable media are disclosed for providing analytics using real time data on movement and proximity of tagged objects for determining location based on participant dynamics/kinetics models. In one embodiment, a method is provided for monitoring a participant that at least includes correlating at least one tag to the participant; receiving blink data transmitted by the at least one tag; and determining tag location data based on the blink data.
12/11/14
20140365194
 Method, apparatus, and computer program product for dynamics/kinetics model selection patent thumbnailMethod, apparatus, and computer program product for dynamics/kinetics model selection
Provided herein are systems, methods and computer readable media for assessing the health, fitness, operation, or performance of an individual. An example method comprises selecting an individual dynamics/kinetics model from a database and comparing it to tag location data.
12/11/14
20140364977
 Method, apparatus, and computer program product for evaluating performance based on real-time data for proximity and movement of objects patent thumbnailMethod, apparatus, and computer program product for evaluating performance based on real-time data for proximity and movement of objects
Systems, methods, apparatuses, and computer readable media are disclosed for providing analytics for evaluating performance using real time data on movement and proximity of tagged objects. In one embodiment, a method is provided for evaluating a player that includes correlating at least one tag to the player; receiving blink data transmitted by the at least one tag; and determining tag location data based on the blink data.
12/11/14
20140364976
 Performance analytics based on real-time data for proximity and movement of objects patent thumbnailPerformance analytics based on real-time data for proximity and movement of objects
Systems, methods, apparatuses, and computer readable media are disclosed for providing performance analytics using dynamics/kinetics models based on role data or weather data and real time data on movement and proximity of tagged objects. In one embodiment, a method is provided for monitoring a participant that at least includes correlating at least one tag to the participant; receiving blink data transmitted by the at least one tag; and determining tag location data based on the blink data.
12/11/14
20140364975
 Method, apparatus, and computer program product for combined tag and sensor based performance modeling using real-time data for proximity and movement of objects patent thumbnailMethod, apparatus, and computer program product for combined tag and sensor based performance modeling using real-time data for proximity and movement of objects
Systems, methods, apparatuses, and computer readable media are disclosed for providing performance modeling by combining tags and sensors providing real time data on movement and proximity of tagged objects. In one embodiment, a method is provided for monitoring a participant that at least includes correlating at least one tag to the participant; receiving blink data transmitted by the at least one tag; determining tag location data based on the blink data; correlating a sensor to the participant; and receiving sensor derived data.
12/11/14
20140364974
 Method, apparatus, and computer program product for performance analytics determining play models and outputting events based on real-time data for proximity and movement of objects patent thumbnailMethod, apparatus, and computer program product for performance analytics determining play models and outputting events based on real-time data for proximity and movement of objects
Systems, methods, apparatuses, and computer readable media are disclosed for providing analytics using real time data on movement and proximity of tagged objects for determining play models and outputting events. In one embodiment, a method is provided for determining play data that at least includes correlating at least one tag to a participant; receiving blink data transmitted by the at least one tag; and determining tag location data based on the blink data.
12/11/14
20140364973
Method, apparatus, and computer program product for monitoring health, fitness, operation, or performance of individuals
Provided herein are systems, methods and computer readable media for monitoring the health and fitness of an individual. An example method comprises correlating a tag and a sensor to the individual, receiving tag derived data indicative of a location for the individual, and receiving sensor derived data indicative of at least one of a health, a fitness, an operation level, or a performance level for the individual.
12/11/14
20140364577
Enhancing the physical properties of semi-crystalline polymers via solid-state shear pulverization
Solid-state shear pulverization of semi-crystalline polymers and copolymers thereof and related methods for enhanced crystallization kinetics and physical/mechanical properties.. .
12/11/14
20140363497
Nanocell drug delivery system
Nanocells allow the sequential delivery of two different therapeutic agents with different modes of action or different pharmacokinetics. A nanocell is formed by encapsulating a nanocore with a first agent inside a lipid vesicle containing a second agent.
12/11/14
20140363428
Therapeutic antigen-binding molecule with a fcrn-binding domain that promotes antigen clearance
The present invention provides: a modified fcrn-binding domain having an enhanced affinity for the fc receptor neonatal (fcrn) at neutral ph; an antigen-binding molecule comprising said fcrn-binding domain, which has low immunogenicity, high stability and form only a few aggregates; a modified antigen-binding molecule having an increased fcrn-binding activity at neutral or acidic ph without an increased binding activity at neutral ph for a pre-existing anti-drug antibody; use of the antigen-binding molecules for improving antigen-binding molecule-mediated antigen uptake into cells; use of the antigen-binding molecules for reducing the plasma concentration of a specific antigen; use of the modified fcrn-binding domain for increasing the total number of antigens to which a single antigen-binding molecule can bind before its degradation; use of the modified fcrn-binding domain for improving pharmacokinetics of an antigen-binding molecule; methods for decreasing the binding activity for a pre-existing anti-drug antibody; and methods for producing said antigen-binding molecules.. .
12/11/14
20140361890
Method, apparatus, and computer program product for alert generation using health, fitness, operation, or performance of individuals
Provided herein are systems, methods and computer readable media for monitoring the health and fitness of an individual. An example method comprises correlating a tag to the individual and receiving tag derived data indicative of a location for the individual, or correlating a sensor to the individual and receiving sensor derived data indicative of at least one of a health, a fitness, an operation level, or a performance level for the individual.
12/04/14
20140357554
Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
Compositions and methods for modulating injection site pain associated with rapid acting injectable insulin formulations have been developed for subcutaneous injection. The formulations contain insulin in combination with a zinc chelator such as ethylenediaminetetraacetic acid (“edta”), a dissolution/stabilization agent such as citric acid, a magnesium salt, and, optionally, additional excipients.
12/04/14
20140357527
Method and apparatus for measuring phosphorylation kinetics on large arrays
The disclosure provides for methods and apparatuses relating to technology for monitoring chemical and/or biological reactions. Some methods provided herein relate to utilization of nappa technology to create large protein arrays suitable for use in combination with various isfet arrays to enable massive parallel assays of kinase activity and inhibition.
11/27/14
20140349959
Polysaccharide gel formulation having increased longevity
Described herein are polysaccharide gel formulations including at least one inhibitor of polysaccharide degradation and methods of making the same. The methods described herein involve the steps of providing at least one polysaccharide and incorporating at least one inhibitor of degradation into the polysaccharide.
11/27/14
20140348963
Pharmaceutical platform technology for the development of natural products
The present invention provides a set of in vitro and in silico methodologies for predicting in vivo pharmacokinetics and pharmacodynamics of multiple components; the methodologies comprise mathematical models for solving multiple unknowns which are linearly independent and/or interacting with each other. The present invention can be applied to develop phytomedicines which contain multiple active ingredients without prior identification, isolation and purification of these components..
11/20/14
20140343078
Compositions and methods for inhibiting cytochrome p450 2d6
Methods of inhibiting cytochrome p450 2d6 enzymes are provided that can be used for improving the treatment of diseases by preventing degradation of drugs or other molecules by cytochrome p450 2d6. Pharmaceutical compositions are provided that can act as boosters to improve the pharmacokinetics, enhance the bioavailability, and enhance the therapeutic effect of drugs that undergo in vivo degradation by cytochrome p450 2d6 enzymes..
11/20/14
20140341994
Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (vmat2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.. .
11/13/14
20140336681
Methods and devices for connecting nerves
A nerve repair conduit configured to be secured on first and second portions of a selected nerve. The nerve repair conduit includes a polymeric body having a proximal end, a distal end, an exterior surface and an interior surface defining an interior lumen.
11/13/14
20140336386
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (vmat2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.. .
11/13/14
20140335157
Cationic lipid having improved intracellular kinetics
And use thereof.. .
11/06/14
20140329810
Aerosol fluoroquinolone formulations for improved pharmacokinetics
The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract..
10/30/14
20140323289
Zeolitic adsorbents for use in adsorptive separation processes and methods for manufacturing the same
A method for producing a zeolitic adsorbent includes providing a zeolite material, providing a zeolite material, providing a first clay binder material and a second clay binder material, the first clay binder material having a greater median particle size than the second clay binder material, determining a desired adsorption kinetics rate for the zeolitic adsorbent, wherein the desired adsorption kinetics rate is based at least in part on a separations process in which the zeolitic adsorbent is desired to be employed, and selecting either the first clay binder material or the second clay binder material based at least in part on the determined desired adsorption kinetics rate. The method further includes blending the zeolite material and the selected first or second clay binder material to form a zeolite/binder blended system, forming a plurality of shaped zeolitic adsorbent pieces from the exchanged zeolite/binder blended system, binder-converting the clay binder material into a zeolite material, and ion-exchanging the binder-converted shaped pieces with an exchange cation to form an ion-exchanged zeolite/binder blended system..
10/30/14
20140322737
Fast reaction kinetics of enzymes having low activity in dry chemistry layers
The present invention concerns a method for determining an analyte as well as a diagnostic element suitable therefore. In one particular form, a method for determining an analyte includes contacting a sample containing the analyte with a diagnostic element comprising a dry reagent layer.
10/30/14
20140320958
Mode-switchable illumination system for a microscope
Illumination system for a microscope system capable of being mode-switchable between a first and a second illumination mode, comprising one source of light for providing a collimated beam of light, at least one selector mirror capable of being positioned in at least two positions to redirect the beam of light in two different beam paths, the first beam path being a direct exit beam path wherein the selector mirror redirects the beam of light along an exit beam path to provide a first illumination mode, the second beam path is a mirror loop path comprising two or more mirrors arranged to redirect the beam of light onto the selector mirror such that it is redirected by the selector mirror a second time along the exit beam path, and wherein mirror loop path comprises at least one optical element arranged to optically alter the beam of light to provide the second illumination mode. According to one embodiment, the first illumination mode is total internal reflection (tirf) and the second illumination mode is photokinetics (pk) illumination..
10/23/14
20140314620
Application of oxygen scavengers to glycol systems
An oxygen scavenger composition is effective in reducing oxygen-induced corrosion in aqueous systems that contain water, oxygen and a significant proportion (at least about 20 wt %) of a glycol, such as monoethylene glycol (meg). The oxygen scavenger composition contains a sulfite, a transition metal salt, and a stabilizer to enhance the kinetics of oxygen removal (scavenging).
10/16/14
20140309161
Modified antibiotic peptides having variable systemic release
The invention relates to modified antibiotic peptides, in particular derivatives of apidaecin and oncocin, preferably having increased stability, reduced immunoreaction, and improved pharmacokinetics. In the invention, the peptide antibiotics are reversibly protected by means of a linker having the polymer polyethylene glycol (peg).
10/16/14
20140308688
Human emulated response with microfluidic enhanced systems
A multiple flow-based microfluidic cell culture system that emulates mammalian physiology is provided. Tissue-mimicking cell cultures are connected by flow within a physiologically meaningful arrangement so that the pharmacokinetics of various agents to be tested in the system emulate in vivo conditions.
10/09/14
20140302999
Method for determination of pharmacological properties of recombinant proteins
The present invention is directed to a method for obtaining an in vitro pharmacological model of a recombinant protein drug in a given host. A plurality of biomolecules are selected which are known or suspected to influence pharmacology of the recombinant protein in the host via a binding interaction with the recombinant protein.
10/09/14
20140302612
Nematic liquid crystal thin films for chemical vapor sensing
A method of detecting an analyte by: providing a device having a substrate, an alignment layer on the substrate, and a film having 4-pentyl-4′-cyanobiphenyl on the alignment layer; exposing the film to air suspected of containing the analyte; measuring a change in a physical property of the film in response to exposing the film; measuring the kinetics of the change in the physical property; and correlating the kinetics to the concentration of the analyte, identification of the analyte, or both.. .
10/09/14
20140302144
Multi-layered injectable self-assembling peptide scaffold hydrogels for long-term sustained release of human antibodies
The invention relates to a pharmaceutical formulation for sustained delivery of a therapeutic agent, preferably a protein, polypeptide, an antibody or an antibody fragment, comprising one or more gel forming peptides wherein the formulation exhibits sustained delivery for at least two weeks, three weeks, four weeks, five weeks, six weeks, seven weeks, eight weeks, nine weeks, ten weeks, eleven weeks, twelve weeks or more. In one embodiment, the invention relates to a formulation comprising self-assembling peptides that undergo sol-gel transition in the presence of an electrolyte solution such as biological fluids and salts.
10/09/14
20140301020
Mesoporous nanocrystalline film architecture for capacitive storage devices
A mesoporous, nanocrystalline, metal oxide construct particularly suited for capacitive energy storage that has an architecture with short diffusion path lengths and large surface areas and a method for production are provided. Energy density is substantially increased without compromising the capacitive charge storage kinetics and electrode demonstrates long term cycling stability.
10/09/14
20140298996
Sorbents for carbon dioxide reduction from indoor air
A sorbent for c02 reduction from indoor air from an enclosed space. In some embodiments, the sorbent comprises a solid support and an amine-based compound being supported by the support.
10/02/14
20140296199
Pharmaceutical delivery systems for hydrophobic drugs and compositions compositions comprising same
A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed.
10/02/14
20140295569
Reagent for detection and assessment of free chlorine in aqueous solution
Provided is a heat dried reagent composition that is dry, methods of making it, and methods of using it. The heat dried reagent composition can be characterized by one or more of stability to the heat drying conditions; storage stability of the heat dried reagent composition; fast rehydration time; rapid assay kinetics; and assay precision.
10/02/14
20140295568
Reagent for detection and assessment of total chlorine in aqueous solution
Provided is a heat dried reagent composition that is dry, methods of making it, and methods of using it. The heat dried reagent composition can be characterized by one or more of: stability to the heat drying conditions; storage stability of the heat dried reagent composition; fast rehydration time; rapid assay kinetics; and assay precision.
10/02/14
20140295094
Combustion deposition systems and methods of use
Combustion deposition systems and methods of using combustion deposition systems are disclosed. In an embodiment, a combustion deposition system may include a burner that is in fluid communication with at least one supply of at least one precursor such that the at least one precursor can be introduced to a flame output from the burner, at least one electrode positioned at least proximate to the flame, and a voltage source operably coupled to the at least one electrode.
09/25/14
20140288317
Aryloxyanilide imaging agents
The present invention provides a novel radiolabelled aryloxyalinine derivative suitable for in vivo imaging. In comparison to known aryloxyalinine derivative in vivo imaging agents, the in vivo imaging agent of the present invention has better properties for in vivo imaging.
09/25/14
20140288036
Novel c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity
Described are steroidal c-17 benzoazoles, pyrimidinoazoles (azabenzoazoles) and diazines. Methods for their synthesis are also described, which include methods having a step of nucleophilic vinylic “addition-elimination” substitution reaction of 3β-acetoxy-17-chloro-16-formylandrosta-5,16-diene or analogs thereof and benzoazole or pyrimidinoazole nucleophiles and methods having a palladium catalyzed cross-coupling reaction of 17-iodoandrosta-5,16-dien-3β-ol or analogs thereof with tributylstannyl diazines.
09/18/14
20140275493
Anti-tfpi antibody variants with differential binding across ph range for improved pharmacokinetics
Antibodies are disclosed that bind to and inhibit the anti-coagulant function of tfpi and have a lower affinity for tfpi at ph 6.0 than at ph 7.4. The lower affinity at ph 6 improves circulating half-life (t½) due to reduced target mediated clearance, a process by which an antibody/antigen complex is endocytosed and trafficked to the lysosome where both components are degraded.
09/18/14
20140274983
Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
Prodrugs of steroidal c-17 benzoazoles, pyrimidinoazoles (az-abenzoazoles) and diazines. Methods of synthesis are also described, whereby a prodrug group is substituted for a functional group at a ring portion of the abc ring structure of the steroid.
09/18/14
20140273044
Method for replacing biomarkers of protein kinetics from tissue samples by biomarkers of protein kinetics from body fluids after isotopic labeling in vivo
Provided herein are method for measuring the rate of synthesis, breakdown, transport, or other kinetic parameters of a protein in a tissue of medical interest, without requiring physical sampling of the tissue, by a measurement of the protein in a body fluid. Methods may include selecting one or more target proteins in a tissue; administering an isotope-labeled molecule to a subject for a period of time sufficient for said isotope-labeled molecule to enter into and label the one or more target proteins to produce one or more isotope-labeled target proteins; collecting a volume of a body fluid, wherein the volume comprises one or more isotope-labeled target proteins that escaped or were released from the tissue; enriching or isolating the one or more isotope-labeled target proteins from the volume; performing a mass spectrometric measurement of the isotopic content, rate of incorporation, and/or pattern or rate of change in isotopic content and/or pattern of isotope labeling of the one or more enriched or isolated isotope-labeled target proteins; and calculating at least one kinetic parameter of the one or more enriched or isolated isotope-labeled target proteins, where the kinetic parameter of the one or more isotope-labeled target proteins from the volume of a body fluid reflects the corresponding kinetic parameter of the one or more target proteins in the tissue; and inferring the at least one kinetic parameter of the one or more target proteins in the tissue based on the corresponding at least one kinetic parameter of the one or more target proteins in the body fluid..
09/18/14
20140271872
Drug delivery system
Disclosed herein are novel methods of treating diseases, novel dosage forms, and novel methods of modulating the pharmacokinetics of active ingredients.. .
09/18/14
20140266194
Method and apparatus for measuring physico-chemical properties using a nuclear magnetic resonance spectrometer
Methods for measuring physico-chemical properties using a nuclear magnetic resonance spectrometer are disclosed, including methods to determine an initial amount of a substance, usually a liquid, contained inside a porous material and an initial amount of the substance, usually a liquid, present outside the porous material, methods to measure the release kinetics of a substance, such as a liquid, from a porous material, and methods for performing chemical reactions and other physico-chemical operations in situ inside a nuclear magnetic resonance probe after a sample is loaded into a nuclear magnetic resonance spectrometer. The apparatuses for performing these methods are also disclosed..
09/11/14
20140255939
Nucleic acid-based linkers for detecting and measuring interactions
The invention provides compositions comprising nucleic acid complexes for use in monitoring binding interactions and in measuring association and/or dissociation kinetics with or without force, detecting analytes, screening aptamers, and encoding/encrypting information. In some instances, the nucleic acid complexes are double-stranded nicked nucleic acids comprising a scaffold nucleic acid hybridized to one or more oligonucleotides.
09/04/14
20140249413
Theranosis of macrophage-associated diseases with ultrasmall superparamagnetic iron oxide nanoparticles (uspio)
Macrophages sequester and aggregate ultrasmall superparamagnetic iron oxide nanoparticles (uspio) in their lysosomes. The amount of uspio loading of macrophages depends upon the route and dose of administration, and the pharmacokinetics of accumulation and removal.
09/04/14
20140249297
Antibodies with modified isoelectric points
The invention relates generally to compositions and methods for altering the isoelectric point of an antibody, and in some cases, resulting in improved plasma pharmacokinetics, e.g. Increased serum half-life in vivo..
09/04/14
20140249136
Parenteral formulations of dopamine agonists
This invention relates to stable pharmaceutical compositions for parenteral administration comprising dopamine agonists and peripheral acting agents useful for treatment of metabolic disorders or key elements thereof. The parenteral dosage forms exhibit long stable shelf life and distinct pharmacokinetics..
09/04/14
20140249124
Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
A drug delivery system for oral administration of hydrophobic drugs with enhanced and extended absorption and improved pharmacokinetics is provided. In one embodiment, formulations comprising testosterone and testosterone esters, e.g., testosterone palmitate, are disclosed.
09/04/14
20140248237
Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
The invention relates to the discovery of novel soluble neutral active hyaluronidase glycoproteins (shasegps), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active shasegp domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain.
08/28/14
20140243340
Cytochrome p450 oxidase inhibitors and uses thereof
Or pharmaceutically acceptable salts, solvates or prodrugs thereof, and methods of using the same to inhibit the metabolizing activities of cyp enzymes. The present invention also features methods of using these compounds, salts, solvates or prodrugs to improve the pharmacokinetics of drugs that are metabolized by cyp enzymes..
08/28/14
20140243331
Inhibitors of inv(16) leukemia
This invention describes the development of targeted small molecule inhibitors of the inv(16) fusion, the causative agent in ˜12% of acute myeloid leukemia (aml). The inv(16) fusion results in expression of the cbfβ-smmhc fusion protein in the blood cells of afflicted patients.
08/28/14
20140238265
Product
A method for manufacturing a cellular geopolymer product, which method comprises the steps: (a) forming an activated geopolymer premix by addition to a geopolymer premix of an activator compound that initiates a condensation reaction in the geopolymer premix; (b) casting the activated geopolymer premix in a desired configuration; and (c) generating gas bubbles in the activated geopolymer premix as the condensation reaction proceeds and the activated geopolymer premix stiffens to produce a self-supporting cellular structure; and (d) curing the self-supporting cellular structure to produce the cellular geopolymer product, wherein in step (c) the characteristics of the activated geopolymer premix and the reaction kinetics of the condensation reaction are controlled to achieve formation of the self-supporting cellular structure.. .
08/21/14
20140236069
Pharmacokinetics of iontophoretic sumatriptan administration
Improved pharmacokinetic profiles for the iontophoretic delivery of sumatriptan are described.. .
08/21/14
20140232029
Kit for measuring the thrombin generation in a sample of a patient's blood or plasma
The invention provides a kit for measuring the thrombin generation in a sample of a patient's blood or plasma, or in a sample of clotting factors. The kit contains lyophilized tissue factor/phospholipid-complex and a lyophilized mixture containing a thrombin-substrate and cacl2.
08/14/14
20140230080
Method for inducing hepatocellular variation, and production method for chimeric non-human animal having humanized liver
The present invention provides (1) a method for producing a non-human animal having a humanized liver, comprising transplanting human hepatic stem cells and/or hepatic progenitor cells and/or immature hepatocytes to a liver-damaged non-human animal to induce the differentiation of the cells into hepatocytes, (2) a non-human animal having a humanized liver, produced by the method, (3) a method for examining the pharmacokinetics and/or hepatotoxicity of a test substance, comprising using the animal, (4) a method for producing human hepatocytes, comprising transplanting human hepatic stem cells and/or hepatic progenitor cells and/or immature hepatocytes to a liver-damaged non-human animal to induce the differentiation of the cells into hepatocytes, and (5) a method for examining the pharmacokinetics and/or hepatotoxicity of a test substance, comprising using human hepatocytes produced by the method.. .
08/07/14
20140221434
Altering pharmacokinetics of pirfenidone therapy
The invention relates to methods for reducing adverse events in patients receiving pirfenidone (5-methyl-1-phenyl-2-(1h)-pyridone) therapy.. .
08/07/14
20140221433
N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
The present invention relates to an improved and shortened synthesis of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acet-amide and the mesylate monohydrate salt thereof by using boronic acid derivatives or borolane reagents while avoiding toxic organic tin compounds and to the mesylate monohydrate salt of n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acet-amide which has demonstrated increased long term stability and release kinetics from pharmaceutical compositions.. .
07/24/14
20140205918
Storage element and method for the production thereof
A storage element for a solid electrolyte battery is provided. The storage element has a main member having a porous matrix of sintered ceramic particles in which particles that are made of a metal and/or a metal oxide and jointly form a redox couple are embedded.
07/24/14
20140205525
Amine promotion for co2 capture
Promoter amines are used to enhance co2 uptake by sterically hindered or tertiary amines. The promoter amines can be cyclic amines, including aromatic cyclic amines or bridged cyclic amines.


Popular terms: [SEARCH]

Kinetics topics: Medical Device, Polypeptide, Nucleic Acid, Nucleic Acids, Specificity, Surfactant, Enhancement, Scattering, Electrolyte, Conductive Elements, Amplification, Red Blood Cell, Red Blood Cells, Antibodies, Luciferase

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Kinetics for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Kinetics with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         



Key IP Translations - Patent Translations



1.0228

3224

449991 - 0 - 72